Plain-English translation of NCT07322887 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called SUL-238 to see if it can help people with early Parkinson's disease. Researchers will measure how the medication affects energy production in brain cells using specialized MRI scans. The study compares two different doses of the medication against a placebo (inactive pill) to find out which works best.
Parkinson's disease damages brain cells over time, and current treatments mainly manage symptoms rather than slow the disease itself. This medication is being tested early in the disease process because researchers believe it may help restore energy production in brain cells, potentially slowing disease progression before symptoms become severe.
You likely qualify if…
You likely don't qualify if…
You will visit the study center 5 times over about 8 weeks. At the first visit, you'll be randomly assigned to receive either a high dose of the medication, a low dose, or a placebo — you won't know which one. You'll take your assigned treatment three times daily for 4 weeks, then have a 4-week follow-up period. During visits, you'll have blood drawn and undergo a special MRI scan that measures brain cell energy. Some participants may also be asked to provide a spinal fluid sample. The entire study takes about 2 months from start to finish.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Netherlands